InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Rhea-AI Summary
InflaRx (Nasdaq: IFRX) closed an underwritten offering of 75,000,000 ordinary shares at $2.00 per share on May 8, 2026, raising aggregate gross proceeds of $150.0 million before underwriting discount and offering expenses. The company said net proceeds will fund pipeline activities, working capital and general corporate purposes.
AI-generated analysis. Not financial advice.
Positive
- $150.0 million gross proceeds raised through the offering
- Net proceeds designated to advance pipeline activities and for working capital
Negative
- Issuance of 75,000,000 ordinary shares will dilute existing shareholders
- Underwriting discount and offering expenses will reduce net proceeds from the $150 million gross amount
News Market Reaction – IFRX
On the day this news was published, IFRX declined 2.64%, reflecting a moderate negative market reaction. Argus tracked a trough of -14.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $202.42M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IFRX was up about 6% while close biotech peers like STTK (-5.86%), SRZN (-12.14%), and MGNX (-2.65%) traded lower, pointing to a stock-specific move rather than a sector rotation.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Offering priced | Negative | +26.9% | Priced 75M-share, $150M underwritten equity offering at $2.00 per share. |
| Feb 18 | Offering closed | Neutral | +1.1% | Closed $30M offering of ordinary shares and pre-funded warrants at $2.00. |
| Feb 13 | Offering priced | Negative | -25.9% | Priced $30M equity and pre-funded warrant offering at $2.00 per share. |
| Feb 13 | Offering announced | Negative | -25.9% | Announced new underwritten public offering of shares and pre-funded warrants. |
Past offerings often saw negative or muted moves, with the latest pricing rally an outlier.
Recent history shows InflaRx using capital markets repeatedly. The latest pricing of a $150 million offering on May 6, 2026 coincided with a strong +26.9% move, contrasting with earlier 2025 offerings that saw sharp declines around -25.93%. Prior financings, including a $30 million raise in February 2025, were used to fund development of vilobelimab and INF904. Today’s closing announcement follows that same financing path, but against a backdrop of the stock trading well above its $1.00 bid-compliance threshold and nearer its 52-week high.
Historical Comparison
Past offering-related headlines saw an average move of about -5.98%, making the current pre-offering gain of roughly +6% notably more constructive than typical.
The company has repeatedly tapped equity markets, evolving from smaller $30M financings in 2025 to the larger $150M raise in 2026 to fund its development pipeline.
Market Pulse Summary
This announcement confirms closing of a large underwritten equity raise of $150 million at $2.00 per share, expanding the share count to roughly 147.3 million. The proceeds are earmarked for pipeline advancement and general corporate purposes, complementing earlier disclosures of funds of about €39.7 million and a projected cash runway through 2029. Investors may watch how capital deployment, trial milestones, and future financing needs evolve relative to this expanded equity base.
Key Terms
underwritten offering financial
offering price financial
underwriting discount financial
shelf registration statement regulatory
prospectus supplement regulatory
U.S. Securities and Exchange Commission regulatory
AI-generated analysis. Not financial advice.
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of
The Company intends to use the net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes.
The financing included participation from new and existing investors, including TCGX, a large healthcare-dedicated fund, Farallon Capital Management, Sirenia Capital Management LP, Columbia Threadneedle Investments, Great Point Partners, LLC, ADAR1 Capital Management, Coastlands Capital, Squadron Capital Management and other large new mutual funds, with participation from existing investors including a leading healthcare fund, 683 Capital, and others.
Guggenheim Securities acted as lead bookrunner for the offering. Oppenheimer & Co. and LifeSci Capital also acted as bookrunners for the offering. Raymond James and Needham & Company acted as co-lead managers for the offering. H.C. Wainwright & Co. and Lucid Capital Markets acted as co-managers for the offering.
A shelf registration statement relating to the ordinary shares sold in this offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on July 11, 2023. The offering was made only by means of a prospectus and prospectus supplement. The prospectus supplement and accompanying prospectus related to the offering were filed with the SEC and are available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of AAV and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
